<SEC-DOCUMENT>0001437749-15-013954.txt : 20150724
<SEC-HEADER>0001437749-15-013954.hdr.sgml : 20150724
<ACCEPTANCE-DATETIME>20150724093119
ACCESSION NUMBER:		0001437749-15-013954
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150724
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150724
DATE AS OF CHANGE:		20150724

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACELRX PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001427925
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35068
		FILM NUMBER:		151003554

	BUSINESS ADDRESS:	
		STREET 1:		351 GALVESTON DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		650-216-3500

	MAIL ADDRESS:	
		STREET 1:		351 GALVESTON DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>acrx20150723_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD><TITLE>acrx20150723_8k.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 10px; MARGIN-RIGHT: 10px">
<P id=PARA1 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif"><B>UNITED STATES</B></FONT></P>
<P id=PARA2 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif"><B>SECURITIES AND EXCHANGE COMMISSION</B></FONT></P>
<P id=PARA3 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>WASHINGTON, D.C. 20549</B></FONT></P>
<P id=PARA4 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA5 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, Times, serif"><B>FORM 8-K</B></FONT></P>
<P id=PARA6 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA7 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>CURRENT REPORT</B></FONT></P>
<P id=PARA8 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B></FONT></P>
<P id=PARA9 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA10 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Date of Report (Date of earliest event reported): </B><B>July 24, 2015</B></FONT></P>
<P id=PARA11 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA12 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman, Times, serif"><B>ACELRX PHARMACEUTICALS, INC.</B></FONT></P>
<P id=PARA13 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Exact name of registrant as specified in its charter)</FONT></P>
<P id=PARA14 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL30  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 30%; VERTICAL-ALIGN: bottom">
<P id=PARA15 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 5%; VERTICAL-ALIGN: bottom">
<P id=PARA16 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 30%; VERTICAL-ALIGN: bottom">
<P id=PARA17 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 5%; VERTICAL-ALIGN: bottom">
<P id=PARA18 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 30%; VERTICAL-ALIGN: bottom">
<P id=PARA19 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 30%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<P id=PARA20 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DELAWARE</B></FONT></P></TD>
<TD style="WIDTH: 5%; VERTICAL-ALIGN: bottom">
<P id=PARA21 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 30%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<P id=PARA22 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>001-35068</B></FONT></P></TD>
<TD style="WIDTH: 5%; VERTICAL-ALIGN: bottom">
<P id=PARA23 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 30%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<P id=PARA24 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>41-2193603</B></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 30%; VERTICAL-ALIGN: top">
<P id=PARA25 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(State of incorporation)</FONT></P></TD>
<TD style="WIDTH: 5%; VERTICAL-ALIGN: bottom">
<P id=PARA26 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 30%; VERTICAL-ALIGN: top">
<P id=PARA27 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Commission File No.)</FONT></P></TD>
<TD style="WIDTH: 5%; VERTICAL-ALIGN: bottom">
<P id=PARA28 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 30%; VERTICAL-ALIGN: top">
<P id=PARA29 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(IRS Employer Identification No.)</FONT></P></TD></TR></TABLE>
<P id=PARA31 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA33 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA32 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>351 Galveston Drive </B></FONT></P>
<P id=PARA34 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Redwood City, CA 94063 </B></FONT></P>
<P id=PARA35 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Address of principal executive offices and zip code)</FONT></P>
<P id=PARA36 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA37 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Registrant&#8217;s telephone number, including area code:</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B> </B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(650) 216-3500 </B></FONT></P>
<P id=PARA38 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA39 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</FONT></P>
<P id=PARA40 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA41 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#9744;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</FONT></P>
<P id=PARA42 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA43 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#9744;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>
<P id=PARA44 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA45 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#9744;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>
<P id=PARA46 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA47 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#9744;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>
<P id=PARA48 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</P>
<DIV id=PGBK51  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR51  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM51  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>

<DIV id=PGHDR51  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA51.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<P id=PARA53 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Item&nbsp;</B><B>8.01. Other Events</B><B>. </B></FONT></P>
<P id=PARA54 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA55 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On July 24, 2015, AcelRx Pharmaceuticals, Inc., or AcelRx, issued a press release titled &#8220;AcelRx Announces Positive CHMP Opinion for Zalviso in the Management of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients.&#8221; A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.</FONT></P>
<P id=PARA89 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA103 style="MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Item 9.01. </B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Financial Statements and Exhibits. </B></FONT></P>
<P id=PARA94 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA93 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 24.5pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(d) Exhibits. </FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 24.5pt">&nbsp;</P>
<TABLE id=TBL100  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="MARGIN-BOTTOM: 0px; WIDTH: 4%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0px">
<P id=PARA95 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Exhibit</B></FONT></P>
<P id=PARA96 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Number</B></FONT></P></TD>
<TD style="MARGIN-BOTTOM: 0px; WIDTH: 2%; VERTICAL-ALIGN: bottom; MARGIN-TOP: 0px">&nbsp; </TD>
<TD style="WIDTH: 94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<P id=PARA97 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 4%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="MARGIN-BOTTOM: 0px; WIDTH: 2%; VERTICAL-ALIGN: middle; MARGIN-TOP: 0px">&nbsp; </TD>
<TD style="WIDTH: 94%">&nbsp;</TD></TR>
<TR>
<TD style="WIDTH: 4%; VERTICAL-ALIGN: top">
<P id=PARA98 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">99.1</FONT></P></TD>
<TD style="WIDTH: 2%; VERTICAL-ALIGN: bottom">&nbsp; </TD>
<TD style="WIDTH: 94%; VERTICAL-ALIGN: top">
<P id=PARA99 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Press Release dated July 24, 2015</FONT></P></TD></TR></TABLE>
<P id=PARA101.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK101  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR101  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM101  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>

<DIV id=PGHDR101  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA101.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase"><B></B></FONT>&nbsp;</P>
<P style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase"><B>Signatures</B></FONT></P>
<P id=PARA60 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA61 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</FONT></P>
<P id=PARA62 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;</P>
<TABLE id=TBL85  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 44.4%; VERTICAL-ALIGN: top">
<P id=PARA68 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Date: July&nbsp;24, 2015</FONT></P></TD>
<TD style="WIDTH: 41.8%; VERTICAL-ALIGN: middle" colSpan=3>
<P id=PARA69 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">ACELRX PHARMACEUTICALS, INC.</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P></TD>
<TD style="WIDTH: 13.8%; VERTICAL-ALIGN: middle">
<P id=PARA71 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 44.4%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 41.8%; VERTICAL-ALIGN: middle" colSpan=3>&nbsp;</TD>
<TD style="WIDTH: 13.8%; VERTICAL-ALIGN: middle">&nbsp;</TD></TR>
<TR>
<TD style="WIDTH: 44.4%; VERTICAL-ALIGN: middle">
<P id=PARA72 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 3.6%; VERTICAL-ALIGN: top">
<P id=PARA73 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">By:&nbsp;&nbsp;</FONT></P></TD>
<TD style="WIDTH: 38.2%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid" colSpan=2>
<P id=PARA74 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">/s/ Jane Wright-Mitchell</FONT></P></TD>
<TD style="WIDTH: 13.8%; VERTICAL-ALIGN: middle">
<P id=PARA75 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 44.4%; VERTICAL-ALIGN: middle">
<P id=PARA76 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 3.6%; VERTICAL-ALIGN: middle">
<P id=PARA77 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 38.2%; VERTICAL-ALIGN: middle" colSpan=2>
<P id=PARA78 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Jane Wright-Mitchell&nbsp;</FONT></P></TD>
<TD style="WIDTH: 13.8%; VERTICAL-ALIGN: middle">
<P id=PARA79 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 44.4%; VERTICAL-ALIGN: middle">
<P id=PARA80 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 3.6%; VERTICAL-ALIGN: middle">
<P id=PARA81 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 38.2%; VERTICAL-ALIGN: middle" colSpan=2>
<P id=PARA82 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Chief Legal Officer</FONT></P></TD>
<TD style="WIDTH: 13.8%; VERTICAL-ALIGN: middle">
<P id=PARA83 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 100%; VERTICAL-ALIGN: middle" colSpan=5>
<P id=PARA84 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR></TABLE>
<P id=PARA86 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT></P>
<DIV id=PGBK104  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR104  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM104  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>

<DIV id=PGHDR104  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA104.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA105 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">EXHIBIT INDEX </FONT></P>
<P id=PARA106 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL113  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 4%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<P id=PARA107 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD style="WIDTH: 2%; VERTICAL-ALIGN: bottom">
<P id=PARA108 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;&nbsp;</FONT></P></TD>
<TD style="WIDTH: 94%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<P id=PARA109 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 4%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 2%; VERTICAL-ALIGN: bottom">&nbsp;</TD>
<TD style="WIDTH: 94%; VERTICAL-ALIGN: top">&nbsp;</TD></TR>
<TR>
<TD style="WIDTH: 4%; VERTICAL-ALIGN: top">
<P id=PARA110 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">99.1</FONT></P></TD>
<TD style="WIDTH: 2%; VERTICAL-ALIGN: bottom">
<P id=PARA111 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;&nbsp;</FONT></P></TD>
<TD style="WIDTH: 94%; VERTICAL-ALIGN: top">
<P id=PARA112 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Press Release dated July 24, 2015.</FONT></P></TD></TR></TABLE>
<P id=PARA114 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML><HEAD><TITLE>ex99-1.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 10px; MARGIN-RIGHT: 10px">
<P id=PARA29 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: right; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Exhibit 99.1</B></FONT></P>
<P id=PARA30 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: left; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: left; MARGIN-TOP: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;<IMG src="logo.jpg" width=275 height=72></P>
<P style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;</P>
<P id=PARA2 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA3 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>AcelRx Announce</B><B>s</B><B> Positive CHMP Opinion for Zalviso in the Management of </B><B>Acute Moderate-to-</B><B>Severe </B><B>Post-Operative </B><B>Pain </B><B>in Adult Patients</B></FONT></P>
<P id=PARA4 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA5 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">REDWOOD CITY, Calif. &#8211; DATE &#8211; AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion for Zalviso&#8482; (sufentanil sublingual tablet system). The opinion, while not binding, recommends marketing authorization for Zalviso for the management of acute moderate-to-severe post-operative pain in adult patients. Zalviso is an investigational drug-device combination product designed to deliver a sublingual formulation of sufentanil 15 mcg via a proprietary pre-programmed, non-invasive, patient-controlled device. Grunenthal Group, AcelRx&#8217;s licensee in Europe, submitted the Marketing Authorization Application (MAA) under the centralized procedure in July of 2014.</FONT></P>
<P id=PARA6 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA7 style="TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 2.5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8220;We believe that Zalviso represents a significant advancement in the management of acute pain, including the moderate-to-severe acute pain experienced by patients recovering from surgery. With this positive opinion from CHMP, Grunenthal and AcelRx are one step closer to bringing a non-invasive, self-dosing, pain management system to the estimated 15.7 million Europeans who undergo surgeries associated with moderate-to-severe post-operative pain every year,&#8221; stated Howie Rosen interim chief executive officer of AcelRx Pharmaceuticals. &#8220;We appreciate the collaborative approach of the CHMP and look forward to continued collaboration with EMA to complete the regulatory process.&#8221;</FONT></P>
<P id=PARA8 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA9 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The positive opinion by the CHMP will next be reviewed by the European Commission for central marketing authorization in the European Union (EU), which has the authority to approve medicines for the 28 member countries of the EU which will also be valid in Norway, Iceland and Liechtenstein. If approved, Grunenthal expects to launch Zalviso beginning in the first half of 2016. In addition, AcelRx would be eligible to receive a $15 million milestone payment from Grunenthal upon approval.</FONT></P>
<P id=PARA10 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA11 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">AcelRx had previously received CE Mark approval of the Zalviso device and ISO certification of its quality management system issued by the British Standards Institution, or BSI, a Notified Body. Under the terms of the collaboration, Grunenthal is responsible for all commercial activities for Zalviso, including obtaining and maintaining pharmaceutical product regulatory approval in the Grunenthal territory. AcelRx will be responsible for maintaining device regulatory approval in the Grunenthal territory and manufacturing and supply of Zalviso to Grunenthal for commercial sales and clinical trials.</FONT></P>
<P id=PARA12 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA13 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>About Zalviso&#8482;</B></FONT></P>
<P id=PARA14 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA15 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Zalviso is an innovative pre-programmed, non-invasive, handheld system that allows hospital patients with acute moderate-to-severe post-operative pain to self-dose with sufentanil sublingual tablets, 15 mcg, to manage their pain. The system is designed to help address certain problems associated with post-operative analgesia, such as the side effects and delayed analgesic effect of morphine, the invasive intravenous (IV) route of delivery of current systems for patient-controlled analgesia (PCA) and the complexity of infusion pumps used for IV PCA delivery. Grunenthal holds the rights for Zalviso in Europe and Australia while AcelRx retains all rights in North America, Asia, Latin America and Middle East/Africa.</FONT></P>
<P id=PARA31.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK31  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR31  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM31  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>

<DIV id=PGHDR31  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</P>
<P style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: right; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><IMG src="logo.jpg" width=275 height=72>&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P>
<P id=PARA17 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>About AcelRx Pharmaceuticals, Inc.</B></FONT></P>
<P id=PARA18 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA19 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. AcelRx&#39;s product candidate, Zalviso, is designed for the management of moderate-to-severe acute pain in adult patients in the hospital setting by utilizing a high therapeutic index opioid, through a non-invasive delivery route via a pre-programmed, patient-controlled analgesia device. AcelRx has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Zalviso in the treatment of moderate-to-severe acute pain in adult patients in the hospital setting and on July 25, 2014, received a Complete Response Letter (CRL) from the FDA. In March 2015, AcelRx received correspondence from the FDA stating that in addition to the bench testing and two Human Factors studies AcelRx had completed in response to the issues identified in the CRL, an additional clinical trial is needed to assess the risk of inadvertent dispensing and overall risk of dispensing failures. AcelRx submitted a formal meeting request to the FDA and this request was denied. AcelRx is currently evaluating its next steps to seek a pathway forward towards gaining approval of Zalviso in the U.S., including potential additional clinical studies, additional Human Factors studies, or the formal dispute resolution process provided for by the FDA. In March 2015, AcelRx initiated SAP301, a pivotal Phase 3 study for ARX-04 (sufentanil sublingual tablet, 30 mcg), a product candidate for the treatment of moderate-to-severe acute pain in a medically supervised setting. AcelRx expects top-line data from this study in the fourth quarter of 2015. The Company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development. For additional information about AcelRx&#39;s clinical programs, please visit www.acelrx.com.</FONT></P>
<P id=PARA20 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA21 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Forward-Looking Statements</B></FONT></P>
<P id=PARA22 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA23 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>This press release contains forward-looking statements, including, but not limited to, statements related to the process and timing of anticipated future development of AcelRx&#39;s product candidates, including </I><I></I><I>Zalviso and </I><I>ARX-04</I><I>; statements related to the </I><I>therapeutic and commercial potential of Zalviso</I><I>; the size of the European market; potential approval and timing of commercial launch of Zalviso in Europe; potential milestone payments under the Grunenthal agreement; </I><I>AcelRx&#39;s plans to seek a pathway forward towards gaining approval of Zalviso in the U.S., including</I><I> </I><I>potential additional clinical studies, additional Human Factors studies, additional data analyses, or the dispute resolution processes provided for by the FDA; </I><I>and </I><I>the </I><I>anticipated timing of the </I><I>Phase 3 ARX-04</I><I>, </I><I>SAP-301 </I><I>trial&#39;s top line results.</I></FONT></P>
<P id=PARA24 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA25 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>These forward-looking statements are based on AcelRx Pharmaceuticals&#39; current expectations and inherently involve significant risks and uncertainties. AcelRx Pharmaceuticals&#39; actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: </I><I>any delays or inability to obtain and maintain regulatory approval of its product candidates, including Zalviso, in the United States and Europe</I><I>,</I><I> and</I><I> ARX-04</I><I>; </I><I>in</I><I>ability to successfully manufacture Zalviso to meet the requirements of Grunenthal</I><I> and potential delays in the timing of the European launch;</I><I> </I><I>the market potential for its product candidates, including Zalviso</I><I>, in the United States and Europe,</I><I> and</I><I> ARX-04</I><I>; </I><I>its ability to obtain sufficient financing to receive regulatory approval for and commercialize Zalviso </I><I>in the United States, </I><I>and complete </I><I>Phase 3 </I><I>clinical development of </I><I>ARX-04; </I><I>AcelRx Pharmaceuticals&#39; ability to finalize the pathway towards timely resubmission of the Zalviso NDA to the FDA, including its ability to use </I><I>the </I><I>dispute resolution process provided for by the FDA; potential additional clinical trials, Human Factors studies, and/or additional data analyses necessary in order to resubmit the Zalviso NDA; </I><I>the ability to maintain compliance with contractual compliance matters and requirements; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals&#39; U.S. Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q filed with the SEC on May 5, 2015. AcelRx Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.</I></FONT></P>
<P id=PARA26 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA28 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!(`1,#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
M@G%-:4(*`%+A>IQ6=XJ\4:=X.T2XU35KZTTW3;*,RW%U=2B*&!1W9F(`'^>]
M>;_M-_M@>#/V5_#/VSQ'J"R:A<*6L=*MB'O+XC^ZO\*`]7;"CIR<`_E]^TM^
MU[X]_;0\8VUC=QW$>GM<!-*\-Z:&D!<D!=P&6GF./O,,#/RJHR32B!]"_M5?
M\%@-1N]2N='^%<,5M8PYC?7[Z'=+<'D9@B885?\`:<$GCY0*YG]FCP)^TU^U
MQ:R:W;_$7Q-X;T%B?*U*_NY8H[P^D$28++S]X?+[GI7H7[%G_!)F'338^*/B
MM`EU?+B:V\.!P\,)_A-T1D.1@?NP2O9BW2OO*RT^*QM8888XX884"1QQH%2-
M1P`HZ`#@8HE9:(#\P_VO_"/QR_8YT/0K[5?C5K^N#7+F6"-;.[N(C$44,2=Y
M.>O`]J^X/V`?%.I>-OV/O`>K:Q?76J:E>Z>SW%U<RF269A+(,LQY)P`/PKYW
M_P""X8_XH?X??]A*[_\`10KWG_@F\VW]AOX<X[Z:W_HZ2A[`>YTF[BO"?C/_
M`,%'OA-\"]7N-+U3Q*-0U>U8I/8Z5`U[);L.JR,GR(PZ;2V[VKQ[5/\`@MOX
M!@EVV/A?Q9>+V9S#%G\`QHY6!]L9HSS7Q#:?\%NO`[2#[5X/\4VZ?WEE@8_D
M6%=YX`_X*Z_!WQK=PV]UJ6K>''F;;YNI61^SH?\`:DC+JH]S@#N0,T<K`^HJ
M*S]%\16GB'2+?4-/NK>^L;N,2P7%O()8IT/(967@@^HS7G?QU_;*^'?[-\ZP
M>+/$EK9ZE(N]-.A5KF\9>Q,<8)53V9MH/K4^0'JF:-U?&7B+_@MG\-[&9ET_
M0/%NH8SAFAB@!_!GS^E9<7_!;WP:\@\SP7XF53SE;B$\?F/YT^5@?<(.:;+_
M`*MJ^1O"G_!9WX3ZS-Y=]:^*]'Y&YY;%9T0>I\MF./PKZ)^$_P`=/"?QY\-?
MVKX1U[3]<LE.V0V[$20-_=DC;#QD^C`$TN5@?DC_`,%$FW?MG?$T=_[0'_I+
M%7ZU?L[*3^SYX%_[%W3_`/TE2OR4_P""AXQ^VG\3?^PBO_I+%7ZW_LY_\F^>
M!/\`L7=/_P#2:.JEL@/.?V\O%NN>"_@.+WP_>:A87PU.WC\RSR)-AW9'`/!K
MXV_X:#^)G_0S>+OQ,G_Q-?IT+59!\VT^V*5;:,_PH?\`@->]E.>4L'1]E.BI
MN][O\NI\SFW#]7&5_:QK."M:RU_R/S$/[0/Q.`_Y&;Q=^<G^%(W[1/Q,@&^3
MQ5XJB1>K.SJ/S(Q7Z??9HR/NI_WR*K7-C!<1LC0PR*V1AE!!KT_]:Z'_`$"Q
M_KY'F?ZH5UMB9?U\S\XO"7[;'Q*\,7$<J^))-3C[PWT0FC?V)X;\CFOM']E/
M]I&S_:.\%W%\MNECJNG.L%_:K)N5&()5U/78P!(STP1VKY,_X*$^`-/\#?'*
M.33+6&UAU>P2ZEBB0(F\,RD@#N0!SZY/>NA_X)@W\UO\8?$EJLC>1=:.)94[
M.T<RA"?H)9,?[YKT\XP&#Q65?VC1@H2T>FG5:/N>5DN88O"YI]0KS<E=K776
MVY]R_P`-21C'>L;Q7XNL?`_A^ZU74IW@T^R3S)Y1"\OEJ.K$("<>IQQS7GB_
MMN_"W[W_``F6F^O^KE_^(K\_HX>M6_A1<O17_(_1JV,HT5^]DHW[NQZ]16#X
M)^(ND?$?08=4T/4+;4]/N"0D\#;E.#@CU!!!X-;?FY7WK.47%VEHS:%2,X\T
M'=#\XHK)\4>*M/\`!VC7&I:K>6]A8V:>9-/.^Q$4=R367\./B_X<^*\5S+X=
MUBUUB.S8+,]N2R1DYP,XQG@]/;U%')+EY[:"]I#GY+Z]CJJ*;O\`\YHJ2QU(
MS;12YKEOBU\8/#OP4\&7'B#Q-JUKHVE6OWIIVYD;LB*.7<]E`)-`'13SA48Y
M^[S]*^,_VS_^"J^D_"N6[\-?#M[77O$D>8KG5&_>:=I;'J%Y_?2#K@?(.Y)R
MM?.?[:'_``4W\2?M#K>:%X7:^\)^"Y,QRJ7$=]J:@C/G.I_=Q\<QHV"#AR1N
M6G?L7?\`!,WQ%^T-]CU[Q1]K\+^"6`EB9DV7VJ+D$>4K?<C(Y\P]?X0<Y%6M
MN!Y;\,?@W\1OVXOBS>-9?;->UBZEWZIK%^^(+($_>E?!"@`';$@/8*N!Q^F_
M[(7[!'A+]D[3?M-K"-8\53(%NM:N5^?H<I"AR(D&2./F;^)CT#OB%^QXVI?!
M^S\`^`?$TWPO\,HC)>)H]D'NKX$8(>X+A_F_B8'>_.6P<5XG'_P1DXQ_PMSQ
M5Q_T[?\`VWVH<FP/MV.W"+T`J7HM?#I_X(R$'_DKGBK_`,!O_ME'_#F9O^BN
M>*O_``'_`/ME2!5_X+A#_BA?A_[:E=_^BEJGJ_QYO/@'_P`$=?`]QI=S+9ZU
MXEA30K">,?-$\LEQ)(P/8B"&8@^N.^*\1_;^_8B_X9(\.^&KH^,M8\5?VQ=3
M0B.]C*+;[4!ROSMR<]L<5T?[3T32?\$E?@`P_P!7'XB4D<]39ZJ`?U/YUHN@
M'/?\$L_V8-"_:'^+VM7GB:QCU+1?"EI'/]BD9A'=7$SD)YAR-RKL=B#G<>N>
M_P"HVD_#'P[H<*PV7A[0[.%>D<%A%&H_`+7PO_P0YNH0_P`3(F_UQ_LR0>NS
M_20?R.*_0;-3)NX&/>>`-#OXVCFT72)HV&&62SC8'Z@K7Q__`,%(OV!+?Q[X
M;TW7OAKX-A'BJ.^$-Y#I@2V6ZMBC'>ZY5-R,J\CYB&(Y'`^V#TK!\<^.=$^&
MWA^;6O$&J6.C:7:NB37=W,(H8R[!%!8\?,S``'N1WQ0I-`?)?[!5E\1/V2_V
M6_B''X]T*ZTNQ\,1R:MHD-T\;(%,+-)&-C'"^8H;'J[8ZU\1?L\^!KS]KG]K
M'0]-UZZNKZ?Q=JKWNKW#OMFDB4/-+\W8^6A7`X&<#M7Z4?M.?&WP;\9?V6?B
M=I_A3Q1H>O7UOX=N+B6"QNDF>.,#!8J.@[9Z5\$_\$K;Z.U_;C\(^<P5KBVO
MT3)_B-I(>_?L!WS5QVN!^H_@;X#^"OA]ID=GHGA'P]IMO"H11#8IN('3+$;F
MZ]22>M;_`/PA>CO&<Z1I?S=OL:?X5X)^T5^Q;XV_:,\3_:+CXQ:[X=TFUD+V
M>E:38FUA@)XW.R2AY7_VG)QGY0,G/G#?\$EO$.?^2[>.OSG_`/DBL@/=_P!H
MW]CGP+\<OAQJUC>>&])M=2:UD-GJ-K:I#<VDH4E&#*`2`V,J<@C(-?FW_P`$
MVOBE?_"7]L3PO;QW$D5GXBNFT/48`?DN!)N$>1ZK-L8'KR1ZY^KE_P""2_B`
MC_DN_CKYN/O3_P#R13?A=_P1UM?A=\4/#OB>/Q_?WLOA_4[?4A"VEJGV@Q2+
M)M+>8<;L$$X[U2>@'QS_`,%$>/VSOB:?^H@/_26*OUM_9S/_`!C[X$_[%W3_
M`/TFCK\DO^"BD;1?MG_$K<K*6U!3C'4&VBP?QS7ZU?LX3+-^SWX%=&4JWAS3
MRISP?]&CHEL@.R\WWJ$W<<9YD56'8G%9_C#3]0U?P_<6^EZ@NEWLR[8[LVXG
M,'^T$)`)'OD>QKYSUO\`X)Q3>*M7N+[4_B+XAO+VZ;?+-+$&9S_WU@#T`X':
MNC"4:,_XT^5>ESAQF(Q%.WL*?,_5(^G/MT;?\MH_^^Q4%WJUK9HS37%M&H!)
M+2`#\R:^7F_X)B6R#/\`PG6M-CM]G'/_`(]7BW[3W[)'B#X`%;Y;VYUSPS,0
MOVL[MULY_AE3)`!/1AP>AP<9]C!Y1@<355*&(U>UXM?F>+C<YQV'I.K+#Z+M
M)?H/_;Q^)-C\1OC[*VF74-]9Z3:)9B>)@T;OEF<`]#@D#(XXKT+_`():>%)K
MGQ5XPUS:ZP6MM;Z?$QZ2.[/)(/\`@(2+_OY7@'P;_P"$/?QM;Q^-O[4_L61M
MCS63A?(89YEXW%!@YV<CJ,CI^E/PC\*^&?"'@FSM?"=M8V^AL@EMS:$,DH;^
M/=DEB>[$DGO7TO$F*C@<OCE=.+MI[W1V=SYCAG#O'8^695&M&W:^NJ.DEMO.
M#*RJRL.XZCTKY._:K_8*74S=>)/`MK'#=`&6ZT=3M2X.<EH>ROC^#A3CC!Z_
M6H;Y:CN>8AGBOA,!F5?!556HNW==&C[_`##*Z&-H^QK+T\C\P?@W\=O$G[.G
MB^2?2Y)$C\S9J&F7*D1S[>&##&Y7&/O?>Y&<BOM;1_VZ/`>H_"=O$\VHM:F`
MB*;36&Z\$V"1$J_Q9VG##Y2.<CFO*_\`@HOX9\`6L,=VS+;^/K@HL4-B@,MZ
MG"@SCT'16^]G`&:^5]7T/5?A[XDC@U739+#4+<I<BVO;;<'7(9<HP^9#QD=#
MT]J_1/J&#SNE'%->SJ=5_-;M_6A^;_VAC,EJRPT)>TAW[?\`!78^I-%\%>-/
MV^O$4>L>)7NO#?PYM9?,L["-\27H'=2/O''64\+GY`.37U9X*\$:9X!T&WTO
M2;&#3]/M5V1P1#"J/ZGW/)KQW]E3]K_1?C5IMOHMY'#HGB2UB"_9%(6&Z"@#
M=!]!CY.J]LCFO>$=6/WJ^'S>6(A5^K5(<BCM'IZ^=^Y]YD=/#3I?6:<N>4M7
M+K?MY>@OE?YS13P6Q17CGN<Q\\_MC?\`!0KPG^RC8R6*M'XB\82+^YT:"X"^
M1GH]PX#>4O?&"S#&!WK\SOB9\8?B!^VA\6;234I+WQ!KEY)Y6FZ58H6CM%)Y
M2&('"CUD.3P"QXP/USO?V2OACJ6H7%U<^!?"MS=7<C2S2RZ=&[RN3DLS$9))
MY)/)K6\"?`KP7\+M0FN_#?AC0-#NKB/RI)K&RCAD=,YVD@9QGG%4I6V`^6?V
M*?\`@E/I_P`-);/Q1\2%L]>\0)B6WTD+YEEIK=C(3GSY!QC("KV#$!J^THH]
MB_=Z=/:EX1.,4J/O%)NX#J***0!03BB@\T`?"7_!<1U_X0?X>DG`_M*Z'/\`
MUR6NA^&7[/[?M/\`_!)/PKX5M6@CU.73%O--EE4%8[F&Y=TY_AW`,A/8.>HX
MKZH\?_"#PQ\58+>+Q-H.DZ]%9N9($O[59Q"Q&"5#9P36AX8\':;X*T"UTK2+
M*UTS3;%=EO:VL0CBA7.<*HX`Z]/6JN!^0_[,OQ]\2?\`!/3X\7TGB+PSJ"Q7
MT!T_5=*N/]'FE4,'62%G&UV1L]R&#$9&0:^ZO"W_``5S^#'B:W62XU;6M'9E
M#>5>Z7)N'XQ[U_(U]%>*/`>C^.=,^Q:YI>FZU9@AO(O[2.XB!]=K@BN#OOV'
M_A#J3LTWPY\)NS<DC3T7/Y4<RZ@<3<_\%2O@C;0M(?&#R;5SM33;G)]ON=:^
M6?\`@H%_P4.T#]JWX?6_P[\`:9K>I_VA?P75S</;$/.(6+I%%",NV9`C%CM&
M$Q_$2OVO;?L)_!VU.4^''A/=[V*G^==OX*^$OAGX;1.GAW0-&T-9!A_L-E%;
MLX]RJ@G\<T<T0/D/_@F?^PMJWPV\!^+-8\=6<FGW/CK3_P"R(],(VW%K9D-O
M>3J%=R1A<<!`3R<#X]\;?"_QK_P3Z_:*TW5-2TF1E\-ZM]JTN^:-DL=6A1SM
MP^"%WQG!3):,N1\VW)_9Q8,9YZ^U0WVCV^J64EK=0PW5K,NR2"6,/'(OH5.0
M:.8#Y7^'W_!8CX0^*K&-]5FUSPS=%1YD-U9F=$8]0KP[@P'T'6NL?_@J/\#X
MDS_PFR_AI]SS_P".5W6K?L;?"O7)VDNOA[X0=VZE-+CC'Y*`*H)^P;\&T/R_
M#GPN/^W04>Z!XU\7O^"PGPMT#PQ?+X<;5O$VK20,MI"MH]K`TA&`7EDQM49R
M2%)XXYKY5_8"\#?$SX_?M!^&]2CUGQE)X7T?4H]2U.^FU*[-CLC._P`E=S[9
M"[`)M`.,L2!C`_2/1_V0?A=X??=9_#_P?"^<[CI4,A!]?F4UWMKI<=C;1P0J
ML4,8V)&BA511P``.`,4<W8#\T_\`@L5^SWJ'A?XP1?$2WLY&T+Q'!%:7MQ&F
MY+.[C0J/,/\`"'C5<$X!((STKU']@[_@I3X'TOX):%X1\;:BWAW6/#=LEC!=
M2QO):WT"?+$P=0=KA<*P/=202#@?;-_I5MJ5I);W44-Q;W";)8I8PZ2J>H*D
M8(/H:\?\8_\`!.GX+^.6D:[\!Z1;R2'+/8&2S/\`Y"91CVQBI`Z3PI^UM\,?
M'6K6=AH_CKPSJ-]?2K#;6\-\C2S.3@*J]<D]J]"""8?U]:\)^&O_``32^$GP
MC^(^E^*M"T74+?5]&E,UHTVISW$<;E"F[;(S`D!CC/0X/85[S%#Y0ZYH`:T6
MP>U4M8T:WUBPFM;JWCN;6X1HY89%#I(I&""#U%:$HRM!3Y3SWSTH3:V)E%-6
MEL?!?[6G[$UU\+7NO$GA>.:^\/,[23V@!:73`>2P(Y:(<^ZX'4"N(_9H_:OU
MK]G74/)C\S5/#5R^9[!GP$_O20GHK<Y(&`V1D#@C])9+%9/O8/KD"O'];_8&
M^%^O:O<WLF@R0273F1UM[V:&,$YSM16`7J>`,<U]E@^)J53#?5,RCSQZ-;H^
M(QG"U:EB?K66SY6]TSO/A?\`%K0_B]X4AUC0KZ.\LYN&P?G@?&2CKU5AGH:\
M?_:-_;&DT'6U\&>`+<^(/&6H-Y&^$>9%8-W]G<#)QD*O!8]CV7A/]B_P/X!_
MM#^Q8]=TO^U(&M[HV^L7*><C`@Y^?KSP1R.Q%;'PC_9I\'?!&6ZE\-Z6MG<7
MG$T\DC3S,O\`=WN2P7C.`<9YKP(3P5.I*:3DE\*=E]_IY'T-2GCZM.--M1?V
MFM_D>>_LT?L>?\(!J_\`PEOC*Z'B+QI?,;B264&1+)SQ\I8_,X7"[\#`&%`%
M=Y\>_P!G;0?V@/#7V'5H?)NH03:7\('VBT8^A[KZJ>#['FO0XXMH[GGTI2NX
M=Q6%3,<1.M]8YO>6UNGH=%'*\-"@\/RW3WOU\S\N_C7\"O$G[.GBQ+74O,6-
MI"]CJEMF.*<@Y#*W\#CCY<Y!/4CFOI#]E/\`;Z76I[;P[XYN([>\8B.UU=B%
MCN#P`LW`"N>S=#WP>3]->.OAUI'Q*\.7&DZY9PW^GW(P\4@Z'LRGJK#L1TKR
MK_AW?\*]O.BWV.A']IW'/_C]?35^(,'CL+[/,:;YTM)(^8H\/8W`XGVN`J+D
M>Z?_``#VA9HY%#;_`+PR,#(HKEO#GP-TWPGHEOIVGZAXA@LK1=D,9U2:38O7
M&6)/?N:*^1Y:?1O[CZQ5,1UBOO/,OVP_C[XV^$GQ!^&'AGP4OA=;SX@:E<:=
M+/K=G-<Q6Q18RC`12QGJQSR>W2IIM*_:5CA;;K_P.D?&5!T+4U!_'[4<5P/_
M``48UG4/#WQY_9[OM)TF37M2M?$-[);:='.D#WCA(<()'^5<^IXKLY/VC?C-
M*H6']GS5!(3A?-\4V&S/N=WZ^U1T.LY'4OVZ?%=C^RK\6]=NM%T+2_B-\)[D
MZ??69:2ZTR>4.@61/F20QNK-@%@1QU[_`$[X%U:77/!>DW]P(Q-?64-S((U(
M0,\:L=H))`R>`37Q1\8/@GXH^''["?[0WBOQQ#8V?BGXB3'5+C3[*?[1#IT(
MDB2.'S.CL!G)';%>N^!_V`/`GC7X9:-?:\WB;5O$EYID$LNM2^(+Y+F.5HE.
MZ)4E"1JO1550`%`Q2`^C_-&>OY4H;Z_E7R!\#?BMJ'BG_@FAK&H>*/']UX;N
M-/%]H_\`PE<P>>ZM(XIS%'*<?/)+MP@(R['');)/)Z+X&^!9\+I]H\&_&B&1
MK3=_PEE[9:W%(6V?\?)=9"\8Z-DH%&>^#0!]U>9D_P!*:LK$\C]*^&;OXF>(
M/'/_``1>U+7-4U:^OM:AMOLQU)IF^T3K%J2QJ[/]YF**`3U(^M>@:]_P3VTG
MQ5\%;&_\/ZIJUG\4'MK2\MO%E]J][-<+<`H[LX$F#&5+*(U4*`1QWH`^J/,R
M..?PHWX'/\J^,[3X33_&S_@HO\1=!\0Z]KW_``C]AX7T:>_TZPU&:SAU.4H0
M`[1LK+'NW,50KN.,Y`(JO\5OV>['X(_M4?#7PKX&UKQ3X2\.?$B&^LM>T^RU
MFY>.>.`12@QF1V:&0X9=\95@K,`1DT`?:F_CO^5'F<D=U]J^-_VO/@-X=_9!
M^'6F_$+X>+K/AWQ#INOZ>EPZZS>7$>J02SK'+%<)+*RNK`]2,YYKM/V[Y/#%
M]XA\":3XH\5>*+339KJYF;PKX=M[J:^\4[54!3]G(=8HNI/`.X@GN`#Z4W\]
M_P`J/,R#MYQ7YY?'?7?A_P#!7PWHGB3X;:'\1OAUXMT_7K'REU.'5+.WU>`S
M!9H7$SM#("A.0V&(!(KV[]IN"X^,G[:_P\^%E]J&J6O@^XT._P#$.K6=C?2V
M9U5HV\J*)Y(F5]JL5?`/.W'0F@#Z@+8]?RI`^6Q7SIXA_8'TWP7KGA_6OA3J
M%[X(UK2M6AN;W?JM]=6FI68SYT$D+RLI+#&#C@BO,?CWXOT7X@_MS>(O#'CY
M?&VJ>!_">A6C66B^'X-0ECDNI_F::=;(;\!?E&XXYXZ4`?;)?%!D_+Z5\-Z:
MGA_P-\>_AK=_!W0_BEHMO=:V+#Q-87VG:O'IMQ82QM^\<78,8:.0*05P1N))
MP!7J'P0O[B7_`(*4?&^V>XN'M[?1]$,4+R,T<9,()*KT&>^*`/I&60F/Y?F^
ME<5X'^.^A_$#XJ>,O!VG_;_[9\"RVT.J>;;%(@;B%9H]C]'^1AG&,'/IFO(O
MVAY96_X*#_`6S\ZX6UO+#7UGB65E28?95QN`/.,Y!['TKRW]G[]DCP#XR_;#
M^/'A^_TO4YM+\-WFF1V$::W?1/&);&*1]TBS!Y,LQ/SLVT'`P*`/KCQ8/&G_
M``L;PW_8O_"-_P#")_OO^$@^V+,;\?*/)^S%3L'S9W;P>.E=:DGR<Y/T&:^6
M_BMX:M_AC^V%^SKX;T5[VST6TAU6%+9KR:7>JP`J'+L3)@G.6)(./:L;X=?#
MC3_VR?VF_C(?'DVK:MH?@C58-"T71UU2YM;*U4(WFR&.%TWN[`'<V?3H!0!]
M?F55')_,4;\CC^5>%_#']E"X^!?Q\M]8\%ZU>:=X!NM+DMM5\-W5[=7RR7>\
M&*>$S.XBP"00",_2O#7TWX5^,/B?XXU#Q.OQ,^-=\VNS0K<:3INIMIF@1HJ#
M[!'Y<BQ.T;%F+IN/[P+GY<``^XY1OX^GM7DG[&OQTUK]H+X9:MK&O0Z;;WEC
MXBU+28EL87CC,-O.8XR0SN2VT#<0<$YP!7DO[$7C'3[']K;XA>#_``K>>(CX
M'M](LM3LM+UE[SSM'N6^2:-4NOWL8/7:>#G(R*X7X=Z9XSU;_@FW\2H/`+:B
M/$DGC+5]@L',=X\']H`S+"W4.8PV,$'K0!]Z'BFJ0W2O@^>T_9GM_#,C7EK\
M1_!6O+:?/J=_;>(X;K39RG^L>8YB+*WS$ABA(]*^OOV>\K\'?#H;Q3_PFV+"
M)1KOR_\`$TP,"4[3C)[^IY/.:`.R9<UXMJ7QZUZQ_;JTWX:K'I?_``CUYX3D
MUZ28P2?;!.LYC"A]^P)@9(V$Y[BO:P<BOF'7#_QMMT'_`+)U+_Z5M0!]-@8'
M3%(7VGYN/K7Q?^S;^SQIO[0GQ1^,S>,-4\1:MH>E^-;NUL]%35[FVLD;.6E9
M8I%+';A5!.%`.!DFNE^$G@FU_9V_X**#P+X9NM6M?!_B'P)<:O)I,^HS75O!
M>0WMO&LL?FLS*?+=U(![CT%`'U:"`O\`]:FAL'G^1KX]_9[^#FC?MF^+_BAX
MG^(3ZQK\6F>+KO0]'L#JUU;6>F6ML551'%#(BACU).2<=>M>N?`K]F:]_9^^
M+?B"YT/7KMOAYJVGPBWT"[N[B\?3KY7.Z6*25FVQLG!4'.0#0![3M!HIBG"_
MPT4`>)_M+_`#7OBQ\;?@[X@TI[%=/\!ZU-J&I"XF*2-&ZQ@>6-IW'Y3U(^M>
MU11#;T_2BB@#S/\`;0^$6J?'G]E_QEX/T-K./5M>LA;VSW4ACA#>8C?,P!(&
M%/8UW7@C2IO#_@[1[&XV^?8V4-O*4.5+)&JG'MD&BB@#YAT']@KQ%K'[!VJ_
M"W5]4T_3=>NM8FU:VNX&:XMT<70GA#\*Q!P`V!D9R,XKT"TU_P#:`U&S339?
M"7PUTJX\ORFU0Z_<W,"'&-ZVX@5CW(0L!T&:**`.%TK]C7Q=8?\`!-34/A*T
MNBMXIN3+LD68K:'=?BX!+!>,IVVXSQ[U].>%-+DT?PMIMI-M,UI:10OM^[N5
M`IQ^(HHH`\K\`_`W7/#7[:GQ`\?7#6+:%XFT73=.LTCE+7"R0!MY=<85>>.3
M4GQI^!^M>/OVF/A/XNL7LETOP7)?MJ"RR%9F$T01/+7!W<CGD444`-_;?^!V
MN?M#?`F3PWH#V<>HMJMC>YNI3''LAG61QD`\X'`QR?SK,_:&^`?B_4_V@_!_
MQ2\#G0[[6O"]A=:3<:3J\\EM!>V\YSNCFC5S'(I[E2".M%%`'%_M'_";XX_M
M4?#5=#O=%^'WA6RAU&TO7A76)]0N+MH9E?Y9/)1(E&,]&8XV\`UVO[17P#\6
MZU\<?!OQ.\!3:-+XB\*VUSIMSIFK2/#;:K:3YROFH&*,C'>/E(.!]"44`8_C
M[X??&7]HU-'T77K/PW\/=!LM5M]2O[K2?$%Q?7]ZD+;OLZ`11!5<_>)8\#H:
MN?$3X%>/?`W[4.H?$_X>KX=U@^(M'ATG5]&U>[EL]_DMF*:*9$?D#(PR]SZY
M!10!-)H7QP^+'Q$\)W.L?\(_\._#/A^_.H:C;Z/K4NHW6O*$*K;,3#&JQ9.6
MSDGY>F"&A\7_``4\??#;]IS7OB5X!L_#OB*/QAIEK8:KI6JW\EA)#);\1RQ2
MK&X(*8!5AUS@T44`9-O\#/BI\0_VM/AW\2/%B>$=,TWPI;W]L^D:;>RW+VBS
M0%`_FO&OFR.[?,`JA4C4#<232ZI\$OBC\(?VD_B-XT\"V/A'Q)I_Q(CLY'@U
M74);"72+B"W2#.5CD$L9V%\`J?FQD8R2B@"IX"_8\\8^#_%WP+O-0URWUZ3X
M?PZDVNWMS=R/-<S72L0(MX)959MHW$?*O3M6BGP/^)7P%^//CCQ9\/[/PKXH
MT/XA3PW][I>J:A+IMQ874:E2T<JQR*Z/N)P5!!QZ444`;G@?X6_$KQS\?M'\
M=>.)M)\-Z?X;TZXLK+P]HNJ3WD=[+,1NGN79(U.T#"`*<$DY%<M\&/A%\7?V
M2M%U3POX7T'P;XT\-S:O=ZGI]Y>:U+IEY`EP_F&*5!#(K,K%OF4C(QQ110!N
M?`SX'?$#1?VK?%'Q&\:-X75?$&A6VG1V^CS2LMJ\3YV'S%!;"\E^,DX"@`5@
M^#/V0_'V@?LE>)O!VF^*H_"/B[4?$U[KNGZEIMS)LC5[H3)%(R!6PZY5P`<`
M]Z**`.CUGQ!^T%K'ABXTAO`?PW6XNK9[:2_D\33RP$LNTR>0;;)7DG86Z<9K
MEKGP]XN_87_92^&?A/PYJFDZEKD>NV6EW0FMGD_M".>9FG2V0<[E4LP)QA8V
M)Q110!]39RGRUXMJ?P(UR[_;PTKXD))8_P#"/6?A*30Y$,I%SYYG,@(3&-N#
MUS110!/^RY\#=;^#WB/XEWFK-8M'XN\57&M6(MW+E8)``N_(&&]1S]:;J'P/
MURZ_;NTOXCJ]C_PCUEX,NM!>-I3]H-S)=02J0N,;=L;9.>O:BB@#C?!WP:^*
MW[,WQ"\;S>!]+\'^+O"?C+6I=?CM-0U.73+S3;B;'FIN6*1'4D#'3I[UTWPC
M^$GQ`U+XYZE\1/&]YIFF2-HRZ/I?A[2-0GNK.W&_>UQ*[J@:4\*-J<+WHHH`
KV/AK;?%Y?!MM_P`)5/X0;7/,F\\V,3^05\U_*QGG/E[,_P"UFBBB@#__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
